Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma. A preliminary report

Drugs in R and D

Volumn 5, Issue 6, 2004, Pages 315-326

  Burzynski, Stanislaw R ^a   Weaver, Robert A ^a   Lewy, Robert I ^a   Janicki, Tomasz J ^a   Jurida, Gabor F ^a   Szymkowski, Barbara G ^a   Khan, Mohammad I ^a   Bestak, Marc ^a  

^a Burzynski Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYLACETAMIDO 2,6 PIPERIDINEDIONE; ANTINEOPLASTON AS2-1; CARBOPLATIN; CORTICOSTEROID;

ADOLESCENT; ANEMIA; ARTICLE; ASTROCYTOMA; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE COURSE; DISEASE DURATION; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLIOMA; HEALTH CARE ORGANIZATION; HUMAN; INFANT; MALE; MEDICAL ASSESSMENT; NAUSEA AND VOMITING; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SOMNOLENCE; TINNITUS; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR LOCALIZATION;

ADOLESCENT; ANTINEOPLASTIC AGENTS; ASTROCYTOMA; BENZENEACETAMIDES; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; GLIOMA; GLUTAMINE; HUMANS; INFANT; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM RECURRENCE, LOCAL; PHENYLACETATES; PIPERIDONES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 10244257525     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200405060-00002     Document Type: Article

References (39)

1. Burzynski SR. The present state of antineoplaston research (1). Integr Cancer Ther 2004; 3: 47-58
2. Burzynski SR. Antineoplastons: history of the research (1). Drugs Exp Clin Res 1986; 1 Suppl. 12: 1-9
3. Burzynski SR. Potential of antineoplastons in diseases of old age. Drugs Aging 1995; 7: 157-67
4. Burzynski SR, Burzynski B, Mohabbat MO. Toxicology studies on antineoplaston AS2-1 injections in cancer patients. Drugs Exp Clin Res 1986; 1 Suppl. 12: 25-35
5. Ashraf AQ, Liau MC, Mohabbat MO, et al. Preclinical studies on antineoplaston A 10 injections. Drugs Exp Clin Res 1986; 1 Suppl. 12: 37-45
6. Burzynski SR, Kubove E, Burzynski B. Treatment of hormonally refractory cancer of the prostate with antineoplaston AS2-1. Drugs Exp Clin Res 1990; 16: 361-9
7. Burzynski SR, Kubove E, Burzynski B. Phase II clinical trials of antineoplastons A10 and AS2-1 infusions in astrocytoma. In: Adam D, editor. Recent advances in chemotherapy. Munich: Futramed Publishers, 1992: 2506-7
8. Burzynski SR, Kubove E, Szymkowski B. Phase II clinical trials of antineoplaston A10 and AS2-1 infusions in high-grade glioma [abstract 5099]. 18th International Congress of Chemotherapy; Stockholm 1993 Jun; 414
9. Burzynski SR, Conde AB, Peters A, et al. A retrospective study of antineoplastons A10 and AS2-1 in primary brain tumors. Clin Drug Invest 1999; 18: 1-10
10. Burzynski SR, Lewy RI, Weaver RA, et al. Phase II study of antineoplastons A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma. Drugs R D 2003; 4: 91-101
11. Tsuda H, Sata M, Ijuuin H. A novel strategy for remission induction and maintenance in cancer therapy. Oncol Rep 2002; 9: 65-8
12. Tsuda H, Sata M, Kumabe T, et al. The preventive effect of antineoplaston AS2-1 on HCC recurrence. Oncol Rep 2003; 10: 391-7
13. Ogata Y, Tsuda H, Matono K, et al. Long-term survival following treatment with antineoplastons for colon cancer with unresectable multiple liver metastases: report of a case. Surg Today 2003; 33: 448-53
14. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38: 143-51
15. Werner BA. Über multiple gliome. Acta Neurochir (Wien) 1959; 6 Suppl.: 227-9
16. Giese A, Bjerkvig A, Berens ME, et al. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 2003; 21: 1624-36
17. Mamelak AN, Prados MD, Obana WG, et al. Treatment options and prognosis for multicentric juvenile pilocytic astrocytoma. J Neurosurg 1994; 81: 24-30
18. Zhu Y, Parada LF. The molecular and genetic basis of neurological tumours. Nat Rev Cancer 2002; 2: 616-25
19. Bos JL. RAS oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-9
20. Costello JF, Plass C, Cavenee WK. Aberrant methylation of genes in low-grade astrocytomas. Brain Tumor Pathol 2000; 17: 49-56
21. Kamitani H, Tanjura S, Watanbe K, et al. Histone acetylation may suppress human glioma cell proliferation with p21WAF1/Cip1 and gelsolin are induced. Neuro-oncol 2002; 4: 95-101
22. Guha A, Feldkamp MM, Lau N, et al. Proliferation of human malignant astrocytomas is dependent on RAS activation. Oncogene 1997; 15: 2755-65
23. Eden A, Gaudet F, Waghmare A, et al. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003; 300: 455
24. Gaudet F, Hodgson JG, Eden A, et al. Induction of tumors in mice by genomic hypomethylation. Science 2003; 300: 489-92
25. Schramke V, Allshire R. Hairpin RNAs and retrotransposon LTRs effect RNAi and chromatin-based gene silencing. Science 2003; 301: 1069-74
26. Shack S, Chen LC, Miller AC, et al. Increased susceptibility of RAS transformed cells to phenylacetate is associated with inhibition of p21ras isoprenylation and phenotypic reversion. Int J Cancer 1995; 63: 124-9
27. Liu -L, Samid D. Mutant p53 as a target of phenylacetate in human glioblastoma [abstract 2580]. 86th Annual Meeting of the American Association for Cancer Research; 1995 Mar; Toronto 36: 433
28. Gorospe M, Shack S, Guyton KZ, et al. Up-regulation and functional role of p21WAF1/Cip1 during growth arrest of human breast carcinoma MCF-7 cells by phenylacetate. Cell Growth Differ 1996; 7: 1609-15
29. Castillo M, Iglesias J, Zafra MF, et al. Inhibition of chick brain cholesterogenic enzymes by phenyl and phenolic derivatives of phenylalanine. J Neurochem 1991; 18: 171-4
30. Adam L, Crepin M, Savin C, et al. Sodium phenylbutyrate induces growth inhibition and Bcl-2 down-regulation and apoptosis in MCF7 RAS cells in vitro and in nude mice. Cancer Res 1995; 55: 5156-60
31. Zhu WG, Lakshmanan RR, Beal MD, et al. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res 2001; 61: 1327-33
32. Waldbillig R, Burzynski SR. Mechanism of action, uptake and gene array studies on the antineoplastic agent phenylacetyl-glutamine (PG) in human glioma cells U-87 [abstract]. Neuro-oncol 2003; 5: 309
33. Waldbillig R, Patil S, Burzynski SR. Uptake and intracellular binding of the antineoplastic agents phenylacetic acid (PN) and phenylacetylglutamine (PG): effects on epigentic mechanisms of gene regulation and gene expression. Report to FDA; 2004 May; 1-26
34. Pathak A, Sharma BS, Kak VK, et al. Multicentric gliomas: report of 2 cases. Indian J Cancer 1993; 4: 205-8
35. Sim KB, Hong SK. Multicentric juvenile pilocytic astrocytoma occurring primarily in the trigone of the lateral ventrile. Childs Nerv Syst 1999; 9: 477-81
36. Zamponi N, Rychlicki F, Ducati A, et al. Multicentric glioma with unusual clinical presentation. Childs Nerv Syst 2001; 17: 101-5
37. Shaw EG, Wisoff JH. Prospective clinical trials of intracranial low-grade glioma in adults and children. Neuro-oncol 2003; 5: 153-60
38. Chamberlain MC, Grafe MR. Recurrent chiasmatic-hypothalamic glioma treated with oral etoposide. J Clin Oncol 1995; 13: 2072-6
39. Mahoney DH, Cohen ME, Friedman HS, et al. Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study. Neuro-oncol 2000; 2: 213-20